Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given an average rating of “Buy” by the ten ratings firms that are covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $46.43.

A number of research firms recently commented on DNTH. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Raymond James lifted their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Wedbush dropped their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock.

Dianthus Therapeutics Trading Down 4.8 %

Dianthus Therapeutics stock opened at $26.35 on Thursday. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77. The stock has a market cap of $779.96 million, a P/E ratio of -10.54 and a beta of 1.84. The stock has a 50 day moving average of $27.70 and a 200-day moving average of $26.64.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts predict that Dianthus Therapeutics will post -2.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in the company. Quest Partners LLC grew its holdings in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares in the last quarter. SG Americas Securities LLC acquired a new position in Dianthus Therapeutics during the 2nd quarter worth $112,000. The Manufacturers Life Insurance Company bought a new position in shares of Dianthus Therapeutics in the second quarter worth $236,000. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at $265,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $334,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.